Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Sight Sciences Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
SGHT
Nasdaq
3841
https://www.sightsciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Sight Sciences Inc
Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2024 Earnings Call Transcript
- May 6th, 2024 2:02 pm
Sight Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
- May 4th, 2024 12:13 pm
Q1 2024 Sight Sciences Inc Earnings Call
- May 3rd, 2024 5:04 pm
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
- May 2nd, 2024 10:20 pm
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
- May 2nd, 2024 8:05 pm
Sight Sciences awarded $34m in Alcon patent infringement case
- Apr 30th, 2024 3:02 pm
Sector Update: Health Care Stocks Edge Higher Late Afternoon
- Apr 29th, 2024 7:55 pm
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
- Apr 29th, 2024 12:05 pm
With 34% ownership, Sight Sciences, Inc. (NASDAQ:SGHT) has piqued the interest of institutional investors
- Apr 22nd, 2024 2:47 pm
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
- Apr 18th, 2024 8:05 pm
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
- Apr 10th, 2024 8:05 pm
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
- Apr 2nd, 2024 8:05 pm
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
- Mar 26th, 2024 8:05 pm
Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2023 Earnings Call Transcript
- Mar 8th, 2024 7:53 pm
Q4 2023 Sight Sciences Inc Earnings Call
- Mar 8th, 2024 2:16 pm
Sight Sciences Inc (SGHT) Navigates Challenges to Maintain Revenue Growth and Reduce Expenses
- Mar 8th, 2024 3:35 am
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates
- Mar 7th, 2024 10:50 pm
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
- Mar 7th, 2024 9:05 pm
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
- Feb 22nd, 2024 9:05 pm
Sight Sciences (SGHT) to Expand in Europe With New Launch
- Feb 21st, 2024 3:25 pm
Scroll